ReviewFrontiers in cell and developmental biology2025
Clinical application of PBMCs in breast cancer: detection, treatment evaluation and prognosis.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma.International journal of molecular sciences · 2026Article
- Autofluorescence lifetime imaging resolves cell heterogeneity within peripheral blood mononuclear cells.Biophotonics discovery · 2026Article
- Autofluorescence lifetime imaging resolves cell heterogeneity within peripheral blood mononuclear cells.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) has superseded lung cancer as the most prevalent malignant neoplasm globally, posing a significant threat to human health. Currently, mammography and ultrasonography serve as the primary modalities for early breast cancer screening. However, X-ray examination exhibits low sensitivity, while ultrasonography has a high false positive rate, which can readily lead to overdiagnosis and overtreatment. Peripheral blood mononuclear cells (PBMCs), which are specialized immune cells generated by hematopoietic stem cells (HSCs), actively monitor any indications of infection, foreign invaders, and abnormal or aberrant cells associated with diseases. Given that PBMCs respond to diverse pathophysiological stimuli in the form of immune responses/immune phenotypic changes, the study of the molecular constituents of PBMCs can facilitate a better understanding of the immune process. Simultaneously, as PBMCs can be isolated from peripheral blood and detected in liquid form, they offer a non-invasive and suitable source of biomarkers. The analysis of PBMCs in cancer patients can be utilized for the early screening and diagnosis of breast cancer, as well as for evaluating therapeutic efficacy and prognosis. This article reviews the clinical application of PBMCs in breast cancer, highlighting its advantages and limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.